From CBC News:
Drug developer Labopharm Inc. (TSX:DDS) received some welcome relief of its own after Health Canada approved the sale of its once-daily painkiller tramadol despite ongoing concerns of U.S. regulators.
The health agency's therapeutic products directorate approved 100-milligram, 200-mg and 300-mg tablets of its formulation of tramadol for the management of moderate pain in adults who require treatment for several days or more, the Laval, Que.-based company said Monday.
"We're excited," Labopharm CEO James Howard-Tripp said in an interview.
"It's very positive for us. Canada is a smaller market than the U.S., but it's still a very important market. It's one of the G8, it's a very serious regulatory body, so it's nice to get approval from that perspective." ...more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment